Work

A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.e16507

Authors: Daniel Costin Danila, Timothy Kuzel, Jeremy Paul Cetnar, Dana E. Rathkopf, Michael J. Morris, Joshi J. Alumkal, Alex Butler, Tracy Curley, Melanie Hullings, Joshua R. Buddle, Julie Filipenko, Howard I. Scher

Institutions: Memorial Sloan Kettering Cancer Center, Northwestern University, Oregon Health & Science University, OHSU Knight Cancer Institute, Sidney Kimmel Center for Prostate and Urologic Cancers

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889675859

Cites:

Cited by: 3

Related to: 10